The Scientists Who Didn’t Get the Memo.

There is a quiet group of scientists scattered across countries and disciplines who share one defining trait: they don’t get the memo. Or, more accurately, they do, and they choose to ignore it.

The memo is never written down. It doesn’t arrive by email or appear explicitly in grant guidelines. Yet everyone in tobacco control understands it. Certain conclusions are welcome. Others are tolerated if they’re carefully hedged, diluted, or framed as unfortunate exceptions. Some are career-limiting. The boundaries are enforced not through censorship, but through softer, more reliable mechanisms: funding decisions, conference invitations, advisory appointments, peer networks, reputational cues. You don’t need to be told where the line is if you watch what happens to people who cross it.

The scientists who don’t get the memo are the ones who follow the evidence anyway.

They are epidemiologists who examine population trends and notice that smoking declines faster when lower-risk nicotine alternatives are widely available. Clinicians who watch patients quit smoking using products public health authorities warn against, not in theory, but in exam rooms, day after day. Toxicologists who compare emissions, biomarkers, and exposure profiles and find steep risk gradients that contradict official messaging. Behavioural scientists who treat people who smoke as agents responding to incentives rather than problems to be managed. They don’t begin with an agenda. They begin with a question, and they end up somewhere inconvenient.

What distinguishes these researchers is not ideology. It is a method.

They rely on real-world data rather than speculative models built on worst-case assumptions. They focus on outcomes rather than intentions. They compare jurisdictions instead of assuming cultural exceptionalism. They examine substitution effects instead of pretending products exist in isolation. And crucially, they listen to people who smoke, a group that is steadily erased from tobacco control discourse and replaced by abstractions, proxies, and moral caricatures.

This last point matters more than is usually acknowledged. Modern tobacco control increasingly speaks about people who smoke, not with them. Their preferences are treated as pathologies. Their behaviour is framed as failure. Their lived experience is dismissed as manipulation. Scientists who take smokers seriously, who ask why people switch, what makes alternatives appealing, and what policies actually change behaviour already sit uncomfortably close to the edge of acceptability.

The response to their work is rarely a direct scientific rebuttal.

Instead, it takes the form of marginalisation by association. Their findings are labelled “controversial,” a word that functions less as a description than as a warning. Their motives are questioned. Their funding sources are scrutinised with a level of zeal rarely applied to institutional actors aligned with prevailing policy. Conflicts of interest are implied rather than demonstrated. Sometimes their work is cited selectively, stripped of its conclusions and repurposed to support the opposite claim. More often, it is simply ignored.

This silence is not accidental. It is structural.

Over time, young researchers entering tobacco control learn which questions are considered responsible and which are considered dangerous. They learn that curiosity has boundaries. That some hypotheses will be praised as socially conscious, while others quietly mark them as unreliable colleagues. This lesson is delivered informally through mentorship, recommendation letters, conference culture, and advice given in private: that topic will be hard to fund, that result will be misused, you don’t want to be associated with that crowd.

Entire lines of inquiry wither not because they lack importance, but because they carry reputational risk. Questions about risk gradients, consumer behaviour, substitution, and unintended consequences are treated as politically fraught, even when they sit at the heart of population health outcomes. The resulting absence of evidence is then misread as evidence of absence, and policy hardens around that void.

This is how a field drifts away from reality without ever announcing that it has done so.

What makes this dynamic particularly revealing is that many of these scientists are not outsiders. They are credentialed, published, and methodologically orthodox. They work in universities. They review papers. They supervise students. Some are deeply embedded in public health systems. The only thing that sets them apart is that they refuse to subordinate results to narrative.

As time passes, a pattern emerges. These researchers stop receiving invitations to panels. They disappear from advisory groups. Their names quietly drop off consultation lists. Their work becomes harder to fund, harder to publish, harder to amplify. Meanwhile, the same small group of “safe” experts is endlessly recycled — offering certainty where the data is complex and moral clarity where the evidence is mixed. Consensus becomes something that is performed rather than tested.

Morality increasingly replaces uncertainty.

Tobacco control presents itself not as a field of competing risks and imperfect tools, but as a moral project with clearly defined heroes and villains. Once a product, behaviour, or finding falls on the wrong side of that moral line, engaging with it becomes suspect regardless of empirical merit. Harm reduction resists this framing by design. It insists on gradients rather than binaries, on trade-offs rather than absolutes, on human behaviour rather than idealised compliance.

Scientists who speak in probabilities instead of certainties are cast as apologists. The language of science, uncertainty, comparison, and relative risk is recoded as ethical weakness. Disagreement is no longer methodological. It is moralised.

There is also a geographic dimension that rarely receives serious attention.

Evidence supporting tobacco harm reduction emerges unevenly across jurisdictions, reflecting differences in regulation, culture, and access. Countries that allow regulated lower-risk alternatives generate natural experiments that contradict dire predictions. Rather than engaging with these comparisons, the field treats them as anomalies or dismisses them as culturally unique. At the same time, harms observed under prohibitionist conditions are routinely generalised as universal truths.

This asymmetry is not caution. It is selective blindness.

As the distance between policy and lived reality widens, enforcement fills the gap. When behaviour fails to align with expectations, the response is tighter regulation, harsher penalties, louder messaging. The possibility that the policy itself is flawed is rarely entertained. Instead, non-compliance is framed as ignorance, moral failure, or industry interference. Scientists who point out that black markets and substitution are predictable responses to product suppression are accused of normalising harm rather than describing it.

This is how descriptive science is mistaken for endorsement.

The costs of persistence accumulate quietly. Hostile peer review focuses on tone rather than method. Colleagues create distance to avoid guilt by association. Invitations dry up. Some researchers leave the field entirely. Others remain, but retreat into technical niches that avoid policy implications. The loss is not just individual careers. It is intellectual diversity and institutional memory.

And yet, the work continues.

It continues because the data does not disappear. Because patients continue to quit smoking with products they are told not to use. Because population trends refuse to obey messaging. Because the ethical obligation to reduce harm outweighs the professional incentive to remain silent. The scientists who don’t get the memo persist not because they are fearless, but because pretending not to see what the evidence shows is incompatible with why they entered science at all.

This is the part of the story that is rarely told: endurance.

Tobacco harm reduction does not need louder slogans or more polished consensus documents. It needs researchers willing to stay in the room when it would be easier to leave. It needs academics who understand that credibility is earned through consistency with reality, not proximity to power. It needs clinicians, epidemiologists, toxicologists, and behavioural scientists prepared to be temporarily unpopular to be ultimately correct.

History is not kind to enforced consensus.

In nutrition, mental health, substance use, and drug policy, it eventually becomes clear which questions are suppressed and which voices are sidelined and how much harm that delay causes. Tobacco harm reduction follows the same path. When the reckoning arrives, it will matter who kept publishing, who kept speaking, and who refused to pretend uncertainty had vanished.

The scientists and academics working in tobacco harm reduction must not give up. (You know who you are)

Not because vindication is guaranteed, but because the people affected by these policies cannot wait for reputational tides to turn. Every year of delay represents real harm: smokers who might have switched but do not, inequities that widen instead of narrow, lives shortened for reasons later described as unintended.

They don’t get the memo.

They keep asking the wrong questions. They keep producing the wrong answers. They keep insisting that outcomes matter more than optics.

And that quiet refusal sustained over years, across disciplines and borders will prove to be the most important contribution of all.